NASDAQ:MSLE

Satellos Bioscience Q3 2026 Earnings Results & Report

$5.78 -0.16 (-2.61%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Satellos Bioscience missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.53 versus the -$0.44 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:05 AM ET

Satellos Bioscience EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Satellos Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Satellos Bioscience Q3 2026 Earnings FAQ

Satellos Bioscience (NASDAQ:MSLE) reported earnings of -$0.53 per share for Q3 2026, missing the consensus estimate of -$0.44. The report was announced on Thursday, November 12, 2026.

Satellos Bioscience Earnings Headlines

FY2026 Earnings Forecast for MSLE Issued By HC Wainwright
Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Satellos Bioscience: Q3 earnings snapshot
See More Satellos Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Satellos Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Satellos Bioscience and other key companies, straight to your email.

About Satellos Bioscience

Satellos Bioscience (NASDAQ:MSLE) is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function.

The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.

Satellos is headquartered in Toronto, Canada. The company was co-founded by Frank Gleeson, who serves as its chief executive officer, and muscle stem-cell researcher Michael Rudnicki.

View Satellos Bioscience Profile